Satellos Bioscience Inc.
MSCLF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $2 | $1 | $6,535 | $0 |
| Gross Profit | -$2 | -$1 | -$6,535 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,950 | $4,435 | $4,542 | $5,531 |
| G&A Expenses | $1,864 | $1,744 | $1,792 | $2,030 |
| SG&A Expenses | $1,948 | $1,744 | $1,792 | $2,030 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $188 | -$3,547 | $252 |
| Operating Expenses | $5,898 | $6,367 | $2,787 | $7,813 |
| Operating Income | -$5,966 | -$6,367 | -$6,479 | -$7,813 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $164 | $791 | $401 | $1,707 |
| Pre-Tax Income | -$5,802 | -$5,576 | -$6,078 | -$6,106 |
| Tax Expense | $19 | $32 | $63 | $0 |
| Net Income | -$5,756 | -$5,608 | -$6,141 | -$6,106 |
| % Margin | – | – | – | – |
| EPS | -0.034 | -0.045 | -0.053 | -0.054 |
| % Growth | 22.9% | 16.3% | 1.3% | – |
| EPS Diluted | -0.034 | -0.045 | -0.053 | -0.054 |
| Weighted Avg Shares Out | 167,339 | 171,227 | 165,824 | 113,027 |
| Weighted Avg Shares Out Dil | 167,339 | 171,227 | 165,824 | 113,027 |
| Supplemental Information | – | – | – | – |
| Interest Income | $345 | $362 | $393 | $257 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $1 | $1 | $12 |
| EBITDA | -$5,963 | -$6,366 | -$6,478 | -$6,094 |
| % Margin | – | – | – | – |